Document text
Principal Investigator: Andrea Marzi
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $46,470
Funding agency: National Institute of Allergy and Infectious Diseases
Summary
1. Intranasal single-dose vaccination with VSV-based COVID-19 vaccines protects hamsters from disease within 10 days
We designed, cloned, and recovered two replication-competent VSV-based vaccines encoding the SARS-CoV-2 spike protein either alone (VSV-SARS2) or in combination with the EBOV GP (VSV-SARS2-EBOV). EBOV GP was included to enable ACE2-independent vaccine replication in the host and to possibly expand target cell tropism. Growth kinetics in cell culture confirmed superior replication of the VSV-SARS2-EBOV vaccine in VeroE6 cells. Using the well-established Syrian golden hamster model of COVID-19, we compared vaccine immunogenicity after a single intranasal (IN) or intramuscular (IM) dose of 105 PFU. IN vaccination resulted in an early CD8+ T cell response in the lungs and a greater total antigen-specific IgG response by ELISA compared to IM-vaccinated and control hamsters. In addition, the neutralizing response was also increased after IN vaccination compared to IM. In contrast, IM-vaccinated hamsters developed an early CD4+ T cell response.
For the protective efficacy study, we vaccinated hamsters IN or IM 28 days prior to challenge with four SARS-CoV-2 VOC: the ancestral, alpha, beta, and delta variants. IN vaccination with either the VSV-SARS2 or VSV-SARS2-EBOV resulted in the highest protective efficacy, as demonstrated by decreased virus shedding and lung viral load in vaccinated hamsters. Histopathologic analysis of the lungs revealed the least amount of lung damage in the IN-vaccinated animals regardless of the challenge virus. In addition, IN-vaccination resulted in protection within 10 days and the animals did not show any clinical or significant histopathologic signs of COVID-19 pneumonia when challenged with the ancestral SARS-CoV-2 strain or the alpha or beta variants. These data demonstrate the ability of VSV-based vaccines to not only protect from disease caused by SARS-CoV-2 VOC, but also to reduce viral shedding (ODonnell et al., Frontiers in Immunology 2021; ODonnell et al., Vaccines 2022).
2. VSV-SARS2-EBOV protected NHPs within 10 days when administered IM but not IN
This project investigated the protective efficacy of a single dose of the VSV-SARS2-EBOV vaccine in rhesus macaques based on the superior performance of this vaccine after IM administration -the approved route for VSV-EBOV vaccination in humans - in hamsters as demonstrated above. We vaccinated NHPs with a single dose of 107 PFU of the vaccine by the IM or IN route, while NHPs vaccinated IN or IM with 107 PFU VSV-EBOV served as controls. Challenge with SARS-CoV-2 WA1 by multiple routes as described previously occurred 10 days later. At 7 days after challenge, all NHPs were euthanized for sample collection. NHPs IM-vaccinated with VSV-SARS2-EBOV were protected within 10 days and did not show signs of COVID-19 pneumonia. In contrast, IN vaccination resulted in limited immunogenicity and enhanced COVID-19 pneumonia compared to controls. The IN-vaccinated NHPs exhibited lung lesions and presented with more lung infiltrates compared to the IM and control groups at the time of euthanasia. Histological examination of the lung tissue revealed immunopathology that was most significant in IN-vaccinated animals. Importantly, IM-vaccinated animals did not develop signs of interstitial pneumonia, nor could we detect SARS-CoV-2 antigen in the lungs. Indeed, at the time of euthanasia, lung lesions were apparent in animals from the IN and control groups, but not in the IM group (Furuyama et al., mBio 2022).
3. SARS-CoV-2 VOC infection induces similar disease but distinct humoral responses and transcriptomic changes in Syrian golden hamsters
There was a critical need to understand the impact of the emerging SARS-CoV-2 VOC on host response and disease dynamics to facilitate the development of vaccines and therapeutics. Syrian golden hamsters are the leading small animal model recapitulating key aspects of severe COVID-19. In this project, we demonstrated that IN inoculation of 105 TCID50 of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1-2020) or VOC first identified in the United Kingdom (alpha, B.1.1.7) and South Africa (beta, B.1.351) led to similar gross and histopathologic pulmonary lesions 4 days after challenge. Although differences in viral genomic copy numbers were noted in the lungs and oral swabs of infected hamsters, infectious titers in the lungs were comparable. At 14 days after challenge, lung pathology was mostly resolved for all challenged hamsters in this non-lethal model. While there was no difference in the S-specific IgG titers at either 14 or 28 days after challenge among the groups, IgG specific to the S receptor-binding domain (RBD) was significantly increased in hamsters infected with B.1.351 compared to B.1.1.7. Antibody neutralization capacities varied, dependent on the original challenge virus and cross-variant protective capacity. Bulk RNA sequencing of lung samples collected 4 days after challenge was performed. Principal component analysis revealed distinct separation between uninfected and infected hamsters, with the B.1.1.7 infection resulting in the most distinct transcriptional profile and the largest number of differentially expressed genes (DEGs)(n=1,277) while infection with B.1.351 resulted in the smallest number of DEGs (n=395). Transcriptional profiling indicated significant induction of antiviral pathways in response to all three challenges with a more robust inflammatory signature in response to B.1.351 infection. Furthermore, no additional mutations in the spike protein were detected at peak disease. These observations document differences in acute early responses or alterations in immune modulation by VOC potentially impacting the efficacy of existing vaccines and therapeutics.
4. Analysis of human COVID-19 serum samples reveals
In order to expand our understanding of human cytokine responses during COVID-19, we analyzed human serum samples collected over time from patients from Indiana. SRAS-CoV-2 infection results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a critical state. Human serum contains abundant evidence of the immune status following infection. Cytokines, chemokines, and antibodies can be assayed to determine the extent to which a patient responded to a pathogen. We examined serum and plasma from a cohort of patients infected with SARS-CoV-2 early in the pandemic and compared them to negative-control sera. Cytokine and chemokine concentrations varied depending on the severity of infection, and antibody responses were significantly increased in severe cases compared to mild to moderate infections. Neutralization data revealed that patients with high titers against an early 2020 isolate had detectable but limited neutralizing antibodies against the emerging SARS-CoV-2 Alpha, Beta and Delta variants. This study highlights the potential of re-infection for recovered COVID-19 patients (Griffin et al., Sci Rep 2021).
We also supported a study by Prof. Ayato Takada (Hokkaido University, Japan) exploring the potential risks of antibody-dependent enhancement (ADE) in COVID-19. Clinical importance of ADE is unclear since the proposed ADE mechanism mostly depends on the Fc receptor (FcR) expressed exclusively on immune cells which are not primary targets of SARS-CoV-2. We show that SARS-CoV-2 utilizes at least two distinct ADE mechanisms, FcR-mediated and FcR-independent complement component C1q-mediated pathways. We found that both FcR- and C1q-mediated ADE activities were detectable in the sera of acute and convalescent COVID-19 patients at a high rate (Okuya et al., Microbiology Spectrum 2022).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><ACE2><Acute><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Response><Antibody-Dependent Enhancement><Antigens><Assay><B.1.1.7><B.1.351><B.1.617.2><Bioassay><Biologic Assays><Biological Assay><Blood Plasma><Blood Serum><C1 q><C1q><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID associated pneumonia><COVID crisis><COVID epidemic><COVID induced pneumonia><COVID infected patient><COVID pandemic><COVID patient><COVID pneumonia><COVID positive patient><COVID related pneumonia><COVID-19><COVID-19 S protein><COVID-19 antigen><COVID-19 associated pneumonia><COVID-19 crisis><COVID-19 detection><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced pneumonia><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 pneumonia><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related pneumonia><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 detection><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cell Culture Techniques><Cells><Chemotactic Cytokines><Clinical><CoV emergence><CoV-2><CoV2><Complement><Complement 1q><Complement C1q><Complement Proteins><Containment><Control Groups><Cricetinae><Data><Data Set><Dataset><Delta variant><Development><Disease><Disorder><Dose><EBOV><EBOV GP><ELISA><Ebola virus><Ebola virus GP gene product><Ebola virus envelope glycoprotein><Ebola-like Viruses><Enzyme-Linked Immunosorbent Assay><Euthanasia><Exhibits><Expression Signature><Fc Receptor><GP Ebola virus><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profile><Gene Expression Profiling><Generalized Growth><Genes><Genetic Alteration><Genetic Change><Genetic defect><Golden Hamsters><Golden Syrian Hamsters><Growth><Hamsters><Hamsters Mammals><Histologic><Histologically><Homologous Chemotactic Cytokines><Human><IgG><Immune><Immune response><Immunes><Immunobiology><Immunoglobulin G><Immunological response><Immunology><Immunomodulation><Immunophysiology><Indiana><Infection><Inflammatory><Intercrines><Interstitial Lung Inflammation><Interstitial Pneumonia><Interstitial Pneumonitis><Interstitial Pulmonary Inflammation><Intramuscular><Japan><Kinetics><Knowledge><Laboratories><Lung><Lung Parenchyma><Lung Respiratory System><Lung Tissue><Lung damage><M mulatta><M. mulatta><Macaca mulatta><Mediating><Mercy Killing><Mesocricetus auratus><Microbiology><Modeling><Modern Man><Molecular Virology><Mutation><Oral><Pathogenesis><Pathway interactions><Patients><Performance><Plasma><Plasma Serum><Principal Component Analyses><Principal Component Analysis><Proteins><Pulmonary Pathology><RNA Seq><RNA sequencing><RNAseq><Research><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><Risk><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 B.1.351><SARS-CoV-2 B.1.617.2><SARS-CoV-2 S protein><SARS-CoV-2 alpha><SARS-CoV-2 antigen><SARS-CoV-2 associated pneumonia><SARS-CoV-2 beta><SARS-CoV-2 delta><SARS-CoV-2 detection><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced pneumonia><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 pneumonia><SARS-CoV-2 positive patient><SARS-CoV-2 related pneumonia><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIS cytokines><Sampling><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><South Africa><South Africa strain><South Africa variant><South African strain><South African variant><Structure of parenchyma of lung><Swab><Symptoms><Syrian Hamsters><T cell response><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Time><Tissue Growth><Transcript Expression Analyses><Transcript Expression Analysis><Tropism><U.K. variant><UK strain><UK variant><United Kingdom><United Kingdom variant><Universities><VSV><Vaccinated><Vaccination><Vaccines><Variant><Variation><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral Burden><Viral Diseases><Viral Load><Viral Load result><Viral Shedding><Virus><Virus Diseases><Virus Shedding><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody receptor><base><cell culture><cell cultures><chemoattractant cytokine><chemokine><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antigen><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 crisis><coronavirus disease 2019 detection><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 pneumonia><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced pneumonia><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease pneumonia><coronavirus disease positive patient><coronavirus disease related pneumonia><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 pneumonia><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><cytokine><design><designing><detect COVID-19><detect COVID19><detect SARS-CoV-2><detect severe acute respiratory syndrome coronavirus 2><develop a vaccine><develop vaccines><development of a vaccine><developmental><differential expression><differentially expressed><ebolavirus><efficacy study><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><enzyme linked immunoassay><frontier><gene expression analysis><gene expression assay><gene expression pattern><gene expression signature><genome mutation><hCoV19><host response><immune modulation><immune regulation><immune system response><immunogen><immunogenicity><immunologic reactivity control><immunological status><immunomodulatory><immunopathology><immunoregulation><immunoregulatory><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lung injury><lung lesion><lung pathology><model of animal><model organism><nCoV><nCoV2><neutralizing antibody><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><ontogeny><outcome following vaccination><outcome following vaccine><pandemic><pandemic disease><pathogen><pathogenic virus><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><protective allele><protective efficacy><protective variant><pulmonary><pulmonary damage><pulmonary injury><pulmonary lesion><pulmonary tissue damage><pulmonary tissue injury><receptor binding><receptor bound><response><result following vaccination><result following vaccine><sample collection><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 detection><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related pneumonia><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><specimen collection><transcriptional differences><transcriptional profile><transcriptional profiling><transcriptional signature><transcriptome sequencing><transcriptomics><vaccination outcome><vaccination result><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine efficacy><vaccine for novel coronavirus><vaccine immune response><vaccine immunogenicity><vaccine outcome><vaccine result><variants of concern><viral genomics><viral infection><viral pathogen><virus genomics><virus infection><virus pathogen><virus-induced disease>